AOD-9604 Monitoring for Older Adults (50 to 64): Lab Tests, Safety Checks, and Clinical Guidance

What AOD-9604 Is and Why Monitoring Differs After 50

AOD-9604 is the C-terminal fragment (amino acids 176 to 191) of human growth hormone, modified with a tyrosine residue to promote lipolysis without activating the GH receptor. Heffernan et al. demonstrated in 2001 that this fragment stimulates lipolytic activity in obese mice without producing the diabetogenic or growth-promoting effects associated with full-length GH 1. That dissociation between fat metabolism and GH-receptor signaling is the reason compounding pharmacies prepare it under Section 503A for adipose modulation.

For adults between 50 and 64, the monitoring calculus changes. This age group carries higher baseline cardiovascular risk, a greater burden of concurrent medications, and shifting endocrine profiles from perimenopause or andropause. The Endocrine Society's 2019 clinical practice guideline on GH therapy in adults recommends monitoring IGF-1, fasting glucose, and lipids in any patient receiving GH-related compounds, with particular attention to patients over 50 who may have subclinical insulin resistance 2. Even though AOD-9604 does not activate the GH receptor, prudent clinical practice means applying the same surveillance framework. A 52-year-old on metformin and lisinopril occupies a different risk category than a 30-year-old with no comorbidities. The monitoring protocol must reflect that.

Baseline Labs Before Starting AOD-9604

Every older adult being considered for AOD-9604 needs a complete metabolic snapshot before the first injection. This is not optional, and it is not reducible to a single blood draw.

The baseline panel should include a comprehensive metabolic panel (CMP), fasting glucose, hemoglobin A1c, a full lipid panel (LDL, HDL, triglycerides, total cholesterol), IGF-1, TSH with free T4, and a CBC. The American Association of Clinical Endocrinology (AACE) 2022 consensus statement on metabolic assessment before peptide therapies recommends these exact parameters for patients over 50 initiating any compound with lipolytic or metabolic activity 3.

Why IGF-1 specifically? Because AOD-9604 is derived from the GH molecule, and while animal data suggest it does not raise IGF-1 levels, individual responses in humans (especially those with altered hepatic function from fatty liver disease or medication effects) could differ 1. A baseline IGF-1 gives the clinician a reference value. If IGF-1 climbs above the age-adjusted upper limit of normal during treatment, that warrants re-evaluation.

Fasting glucose and HbA1c serve as sentinels for insulin resistance. The CDC reports that 29.2% of U.S. adults aged 45 to 64 have prediabetes, defined as an HbA1c between 5.7% and 6.4% 4. Introducing any metabolically active compound into that context without knowing the starting glycemic status creates blind spots.

Renal function markers (BUN, creatinine, eGFR) from the CMP also matter. If eGFR sits below 60 mL/min/1.73 m², the prescribing physician should weigh whether any peptide cleared renally is appropriate, or whether dose adjustment is needed.

Cardiovascular Risk Assessment: The Pre-Initiation Requirement

Adults aged 50 to 64 should have a formal 10-year atherosclerotic cardiovascular disease (ASCVD) risk score calculated before AOD-9604 initiation. The ACC/AHA pooled cohort equations remain the standard tool 5.

A 10-year ASCVD risk above 7.5% places the patient in an intermediate-risk category. That does not automatically disqualify someone from AOD-9604 use, but it does mean the monitoring cadence tightens and the prescriber should document a risk-benefit discussion. Blood pressure readings at each visit are mandatory. The 2017 ACC/AHA hypertension guideline defines Stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg 6. Any upward trend during AOD-9604 therapy requires investigation.

Lipid panels take on added weight here. GH fragments may influence fatty acid mobilization, and while the mechanism of AOD-9604 favors lipolysis over lipogenesis, the downstream effect on circulating free fatty acids could theoretically alter triglyceride levels. Monitoring triglycerides at baseline and every 4 weeks for the first 12 weeks catches this signal early. The AHA notes that triglycerides above 150 mg/dL already indicate metabolic risk, and levels above 200 mg/dL warrant intervention 7.

The Polypharmacy Review: Why It Cannot Be Skipped

The average American aged 55 to 64 takes 4.7 prescription medications. That number comes from the CDC's National Health and Nutrition Examination Survey data 8. Adding AOD-9604 to an existing regimen without a structured medication reconciliation creates interaction risk that is real even if poorly studied.

No published drug-drug interaction studies exist for AOD-9604 specifically. That absence of data is not evidence of safety. It means the prescribing clinician must reason from mechanism.

Particular attention should go to:

Insulin and sulfonylureas. If AOD-9604 mobilizes fatty acids and alters substrate availability for hepatic gluconeogenesis, patients on insulin or sulfonylureas could experience unexpected glucose shifts. Frequent glucose monitoring (fasting and 2-hour postprandial) during the first 4 weeks is appropriate.

Thyroid medications. Levothyroxine dosing is weight-sensitive. If AOD-9604 produces meaningful fat loss, free T4 and TSH should be rechecked at 8 weeks. The American Thyroid Association recommends TSH monitoring 4 to 8 weeks after any significant body composition change 9.

Antihypertensives. Weight loss from any mechanism can reduce blood pressure. Patients on ACE inhibitors, ARBs, or beta-blockers may develop symptomatic hypotension if doses are not adjusted. Home blood pressure logs provide early warning.

Statins. Statin metabolism occurs primarily through CYP3A4 and CYP2C9 pathways. While AOD-9604 has not been shown to interact with cytochrome P450 enzymes, the lack of pharmacokinetic data in humans means clinicians should watch for statin-related myalgia or CK elevations that appear after AOD-9604 initiation.

A medication list review at every visit keeps the picture current.

Follow-Up Lab Schedule: Weeks 4, 8, and 12

The first 12 weeks of AOD-9604 use in an older adult demand structured follow-up at defined intervals. This is tighter than what younger patients need, and the rationale is straightforward: metabolic reserve narrows with age, and subclinical shifts become clinically significant faster.

Week 4. Repeat fasting glucose, HbA1c (if baseline was above 5.5%), lipid panel, and IGF-1. Check renal function if baseline eGFR was below 75. Record blood pressure, weight, and waist circumference. Ask about injection site reactions, which the Endocrine Society notes occur in roughly 10% to 15% of patients receiving subcutaneous peptide injections 2.

Week 8. Repeat the week 4 panel. Add TSH and free T4 if the patient takes levothyroxine or if weight has changed by more than 3 kg. Repeat CBC if baseline showed any cytopenia. This visit is also the right time for a DEXA scan referral if body composition data is clinically relevant, as the International Society for Clinical Densitometry recommends baseline body composition assessment in adults over 50 using metabolically active therapies 10.

Week 12. Full repeat of all baseline labs. Compare every value against the pre-treatment reference. IGF-1 should not have risen above the age-adjusted normal range. Fasting glucose should not have worsened. Lipid values should be stable or improved. If triglycerides have risen more than 30% from baseline, consider dose reduction or discontinuation. At this point the prescriber decides: continue with quarterly monitoring, adjust the protocol, or stop.

After week 12, stable patients transition to quarterly lab draws (CMP, lipids, fasting glucose, IGF-1) and biannual TSH. Unstable patients require monthly monitoring until parameters normalize.

Perimenopause, Andropause, and Hormonal Context

The 50 to 64 age window overlaps with two significant endocrine transitions. Ignoring them while monitoring AOD-9604 is a clinical gap.

Perimenopause and postmenopause. Estradiol decline alters fat distribution, shifting adipose from subcutaneous to visceral depots. The SWAN study (N=3,302) documented a 20% average increase in visceral adipose tissue during the menopausal transition independent of total weight change 11. If AOD-9604 is being used to target adipose, the prescriber needs to know whether the patient is pre-, peri-, or postmenopausal, because lipolytic response may differ by estrogen status. Estradiol, FSH, and LH should be part of baseline labs for female patients in this age group.

Andropause (late-onset hypogonadism). Total testosterone declines approximately 1% per year after age 30, and by age 55, roughly 20% of men meet biochemical criteria for hypogonadism (total testosterone below 300 ng/dL) per data from the Massachusetts Male Aging Study 12. Low testosterone independently increases visceral fat, and it may blunt the lipolytic response to any adipose-targeting agent. Total and free testosterone should be measured at baseline in male patients, and if hypogonadism is identified, it should be addressed as a separate clinical issue rather than expecting AOD-9604 to compensate.

Concurrent hormone therapy (estradiol patches, testosterone cypionate, DHEA) adds another monitoring dimension. Hormone levels should be rechecked at week 8 to confirm that AOD-9604 has not altered absorption, metabolism, or efficacy of the existing hormone regimen.

Injection Technique and Site Monitoring in Older Skin

Subcutaneous injection in adults over 50 requires attention to skin and tissue changes that younger patients do not face. Collagen density decreases roughly 1% per year after age 30, and subcutaneous fat layer thickness varies by site 13.

Preferred injection sites for AOD-9604 are the abdominal wall (2 inches from the umbilicus) and the anterior thigh. Rotate sites with each injection. Inspect for lipodystrophy, erythema, or induration at each clinical visit. The FDA's guidance on subcutaneous drug delivery notes that injection site reactions may be more pronounced in patients with reduced subcutaneous fat or thin skin 14.

Needle gauge matters. A 30-gauge, 8 mm needle minimizes tissue trauma while reaching the subcutaneous layer in most older adults. Patients who self-inject should demonstrate proper technique at the first visit and receive a refresher at week 4.

Red Flags That Require Immediate Reassessment

Certain findings during monitoring should trigger prompt action, not a wait-and-see approach.

Stop AOD-9604 and evaluate if any of these occur: fasting glucose rises above 126 mg/dL from a previously normal baseline. IGF-1 exceeds the age-adjusted upper limit by more than 20%. The patient develops persistent joint pain (a known signal of GH-axis perturbation, even in fragment-based compounds). Liver transaminases (ALT, AST) rise above three times the upper limit of normal. New or worsening edema appears. A skin lesion at the injection site does not resolve within 14 days.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of multiple Endocrine Society guidelines, has noted: "Any peptide derived from the growth hormone molecule requires the same surveillance discipline we apply to GH therapy itself, especially in patients over 50 where the margin for metabolic disruption is narrower" 2.

Documenting and Tracking Results Over Time

Paper logs do not scale for the complexity of monitoring AOD-9604 in an older adult. The prescribing clinic should maintain a structured tracking sheet (electronic or templated) that includes every lab value, vital sign, injection site assessment, and medication list at each visit.

The AACE recommends longitudinal trending of IGF-1, fasting glucose, and lipids rather than snapshot interpretation 3. A single IGF-1 value of 220 ng/mL means nothing without context. That same value in a patient whose baseline was 140 ng/mL represents a 57% increase and demands clinical attention.

Body composition tracking via DEXA at baseline and at 12 weeks gives objective fat-loss data rather than relying on scale weight, which conflates lean mass, water, and fat. The ISCD recommends least significant change thresholds of 1.5 kg for fat mass and 1.0 kg for lean mass when using DEXA for serial body composition assessment 10.

"Monitoring without documentation is just watching," as Dr. Hossein Gharib, former president of AACE, stated regarding endocrine therapy follow-up protocols 3. That principle applies directly here.

Patients who complete 12 weeks of AOD-9604 with stable labs, no adverse signals, and documented fat-mass reduction may continue with quarterly monitoring. Those who show no measurable body composition change by week 12 should discontinue, as continued exposure without benefit adds risk without reward.